We are live on ! Find out more
XENE icon

Xenon Pharmaceuticals
XENE

31 hedge funds and large institutions have $80.8M invested in Xenon Pharmaceuticals in 2016 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 5 increasing their positions, 10 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

58.65% more ownership

Funds ownership: 0% → 58.65% (+59%)

20% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 5

3% more funds holding

Funds holding: 30 → 31 (+1)

0% more capital invested

Capital invested by funds: $80.6M → $80.8M (+$212K)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

50% less repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 10

Holders
31
Holders Change
+1
Holders Change %
+3.33%
% of All Funds
0.78%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.07%
New
6
Increased
5
Reduced
10
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
Capital World Investors
Capital World Investors
California
+$1.57M
2
Millennium Management
Millennium Management
New York
+$1.56M
3
SFM
Sphera Funds Management
Israel
+$803K
4
EIM
Essex Investment Management
Massachusetts
+$564K
5
California Public Employees Retirement System
California Public Employees Retirement System
California
+$442K

Top Sellers

1
HCMT
Highland Capital Management (Texas)
Texas
-$1.12M
2
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
-$972K
3
BI
BVF Inc
California
-$523K
4
Point72 Asset Management
Point72 Asset Management
Connecticut
-$388K
5
PA
Perceptive Advisors
New York
-$181K
Name Holding Trade Value Shares
Change 		Change in
Stake
Deutsche Bank
26
Deutsche Bank
Germany
$98K -$128K -15,986 -56%
Geode Capital Management
27
Geode Capital Management
Massachusetts
$77K +$80.5K +10,020 New
Bank of Montreal
28
Bank of Montreal
Ontario, Canada
$56K – – –
Wells Fargo
29
Wells Fargo
California
$19K +$402 +50 +2%
Morgan Stanley
30
Morgan Stanley
New York
$9K -$13.5K -1,675 -60%
Citigroup
31
Citigroup
New York
$5K – – –
LWIC
32
Leith Wheeler Investment Counsel
British Columbia, Canada
– -$171K -16,075 Closed
M&T Bank
33
M&T Bank
New York
– -$115K -14,251 Closed
JP Morgan Chase
34
JP Morgan Chase
New York
– -$14K -1,700 Closed
TRCT
35
Tower Research Capital (TRC)
New York
– -$8K -997 Closed
UBS Group
36
UBS Group
Switzerland
– -$5K -617 Closed
1
2

XENE Hedge Fund Activity: Q4 2016 in Review

31 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Xenon Pharmaceuticals (XENE) for Q4 2016, worth a combined $80.8M — up 0.26% from $80.6M a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new XENE positions and 5 closed out — a net gain of 1 holder — while 5 added to existing stakes and 10 trimmed.

The largest buyer was Capital World Investors, adding an estimated $1.57M. The largest seller was Highland Capital Management (Texas), cutting an estimated $1.12M.

  • 31 institutional investors held Xenon Pharmaceuticals (XENE) as of Q4 2016, up from 30 in Q3 2016.
  • Funds reported $80.8M of Xenon Pharmaceuticals stock for Q4 2016, up 0.26% quarter-over-quarter.
  • 6 funds opened new Xenon Pharmaceuticals positions in Q4 2016 and 5 closed out, a net change of +1 holder.
  • The largest Xenon Pharmaceuticals buyer in Q4 2016 was Capital World Investors, an estimated $1.57M added.
  • The largest Xenon Pharmaceuticals seller in Q4 2016 was Highland Capital Management (Texas), an estimated $1.12M sold.

Based on aggregated 13F filings for Q4 2016.